The role of prefibrillar assemblies in the pathogenesis of amyloid diseases

Drugs of the Future

Volumn 29, Issue 6, 2004, Pages 613-619

  Gazit, Ehud ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLIN; AMYLOID BETA PROTEIN; CALCITONIN; FIBRINOGEN; GELSOLIN; HUNTINGTIN; IMMUNOGLOBULIN LIGHT CHAIN; INSULIN; LYSOZYME; PREALBUMIN; PROLACTIN; SERUM AMYLOID A;

ALZHEIMER DISEASE; AMYLOIDOSIS; BETA SHEET; CELL ULTRASTRUCTURE; CYTOTOXICITY; HUMAN; MEMBRANE PERMEABILITY; MOLECULAR RECOGNITION; NON INSULIN DEPENDENT DIABETES MELLITUS; PARKINSON DISEASE; PATHOGENESIS; PRION DISEASE; PROTEIN ASSEMBLY; REVIEW; SYSTEMIC DISEASE; X RAY DIFFRACTION;

EID: 3943112377     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.06.853453     Document Type: Review

References (40)

1. Harper, J.D., Lansbury, P.T. Jr. Models of amyloid seeding in Alzheimer disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 1997, 66: 385-407.
2. Sunde, M., Blake, C.C.F. From the globular to the fibrous state: Protein structure and structural conversion in amyloid formation. Quart Rev Biophys 1998 31: 1-39.
3. Dobson, C.M. Protein misfolding, evolution and disease. Trends Biochem Sci 1999, 24: 329-32.
4. Sipe, J.D., Cohen, A.S. Review: History of the amyloid fibril. J Struct Biol 2000, 130: 88-98.
5. Gazit, E. Mechanistic studies of the process of amyloid fibrils formation by the use of peptide fragments and analogues: Implications for the design of fibrillization inhibitors. Curr Med Chem 2002, 9: 1725-35.
6. Jarrett, J.T., Lansbury, P.T. Jr. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993, 73: 1055-8.
7. Guijarro, J.I., Sunde, M., Jones, J.A., Campbell, I.D., Dobson, C.M. Amyloid fibril formation by an SH3 domain. Proc Natl Acad Sci USA 1998, 95: 4224-8.
8. Chiti, F, Webster, P., Taddei, N., Clark, A., Stefani, M., Ramponi, G., Dobson, C.M. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA 1999, 96: 3590-4.
9. Serio T.R., Lindquist S.L. The yeast prion [PSI+]: Molecular insights and functional consequences. Adv Protein Chem 2001, 59: 391-412.
10. Tuite, M.F., Cox, B.S. Propagation of yeast prions. Nat Rev Mol Cell Biol 2003, 4: 878-90.
11. Chapman, M.R., Robinson, L.S., Pinkner, J.S., Roth, R., Heuser, J., Hammar, M., Normark, S., Hultgren, S.J. Role of Escherichia coli curli operons in directing amyloid fiber formation. Science 2002, 295: 851-5.
12. Harper, J.D., Wong, S.S., Lieber, C.M., Lansbury, P.T. Jr. Observation of metastable A amyloid protofibrils by atomic force microscopy. Chem Biol 1997, 4: 119-25.
13. Walsh, D.M., Lomakin, A., Benedek, G.B., Condron, M.M., Teplow, D.B. Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 1997, 272: 22364-72.
14. Conway, K., Harper, J.D., Lansbury, P.T. Jr. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat Med 1998, 4: 1318-20.
15. Lashuel, H.A., Lai, Z., Kelley, J.W. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: Implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry 1998, 37: 17851-64.
16. Goldsbury, C., Kistler, J., Aebi, U., Arvinte, T, Cooper, G.J.S. Watching amyloid fibrils grow by time-lapse atomic force microscopy. J Mol Biol 1999, 285: 33-9.
17. Porat, Y., Kolusheva, S., Jelinek, R., Gazit, E. The human islet amyloid polypeptide forms transient membrane-active protofilaments. Biochemistry 2003, 42: 10971-7.
18. Srinivasan, R., Jones, E.M., Liu, K., Ghiso, J., Marchant, R.E., Zagorski, M.G. pH-dependent amyloid and protofibril formation by the ABri peptide of familial British dementia. J Mol Biol 2003, 333: 1003-23.
19. Hartley, D.M., Walsh, D.M., Ye, C.P., Diehl, T., Vasquez, S., Vassilev, P.M., Teplow, D.B., Selkoe D.J. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999, 19: 8876-84.
20. Walsh, D.M., Hartley, D.M., Kusumoto, Y, Fezoui, Y., Condron, M.M., Lomakin, A., Benedek, G.B., Selkoe, D.J., Teplow, D.B. Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999, 274: 25945-52.
21. Ward, R.V., Jennings, K.H., Jepras, R., Neville, W., Owen, D.E., Hawkins, J., Christie, G., Davis, J.B., George, A., Karran, E.H., Hewlett, D.R. Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of β-amyloid peptide. Biochem J 2000, 348: 137-44.
22. Nilsberth, C., Westlind-Danielsson, A., Eckman, C.B., Condron, M.M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D.B., Younkin, S.G., Naslund, J., Lannfelt, L. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat Neurosci 2001, 4: 887-93.
23. Lashuel, H.A., Petre, B.M., Wall, J., Simon, M., Nowak, R.J., Walz, T., Lansbury P.T. Jr. α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002, 322: 1089-102.
24. Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T., Lansbury, P.T. Jr. Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature 2002, 418: 291.
25. Lashuel, H.A., Hartley, D.M., Petre, B.M., Wall, J.S., Simon, M.N., Walz, T., Lansbury, P.T. Jr. Mixtures of wild-type and a pathogenic (E22G) form of Aβ40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol 2003, 332: 795-808.
26. Volles, M.J., Lansbury, P.T. Jr. Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002, 41: 4595-602.
27. Gazit, E., La Rocca, P., Sansom, M.S.P., Shai, Y. The structure and organization within the membrane of the helices composing the pore-forming domain of Bacillus thuringiensis d endotoxin are consistent with an "umbrella-like" structure of the toxin pores. Proc Natl Acad Sci USA 1998, 95: 12289-94.
28. Anguiano, M., Nowak, R.J., Lansbury, P.T. Jr. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 2002, 41: 11338-43.
29. Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300: 486-9.
30. Lansbury, P.T. Jr. Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci USA 1999, 96: 3342-4.
31. Azriel, R., Gazit, E. Analysis of the structural and functional elements of the minimal active fragment of islet amyloid polypeptide (IAPP): An experimental support for the key role for the phenylalanine residue in amyloid formation. J Biol Chem 2001, 276: 34156-61.
32. Mazor, Y., Gilead, S., Benhar, I., Gazit, E. Identification and characterization of a novel molecular-recognition and self-assembly domain in the islet amyloid polypeptide. J Mol Biol 2002, 322: 1013-24.
33. Gazit, E. A possible role for π-stacking in the self-assembly of amyloid fibrils. FASEB J 2002, 16: 77-83.
34. Gazit, E. Global analysis of tandem aromatic octapeptide repeats: The significance of aromatic-glycine motif. Bioinformatics 2002, 18: 880-3.
35. Reches, M., Porat, Y., Gazit, E. Amyloid fibrils formation by penta-and tetrapeptide fragments of human calcitonin. J Biol Chem 2002, 277: 35475-80.
36. Reches, M., Gazit, E. Casting metal nanowires within discrete self-assembled peptide nanotubes. Science 2003, 300: 625-7.
37. Salomon, A.R., Marcinowski, K.J., Friedland, R.P., Zagorski, M.G. Nicotine inhibits amyloid formation by the β-peptide. Biochemistry 1996, 35: 13568-78.
38. Thomas, T., Nadackal, T.G., Thomas, K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-aggregation. Neuroreport 2001, 12: 3263-7.
39. Forloni, G., Colombo, L., Girola, L., Tagliavini, F., Salmona, M. Anti-amyloidogenic activity of tetracyclines: Studies in vitro. FEBS Lett 2001, 487: 404-7.
40. Cordeiro, Y., Lima, L.M., Gomes, M.P., Foguel, D., Silva, J.L. Modulation of prion protein oligomerization, aggregation, and - sheet conversion by 4:4′-dianilino-1,1′-binaphthyl-5,5′-sulfonate (bis-ANS). J Biol Chem 2004, 279: 5346-52.